A Study to Assess Change in Disease Activity in Adolescents and Adults With Moderate to Severe Prurigo-type Atopic Dermatitis in Japan Who Are Treated With Oral Upadacitinib

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Atopic Dermatitis
Trial Locations (1)

983-0005

RECRUITING

Tohoku Medical and Pharmaceuti /ID# 252486, Sendai

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY